Chapter 305 - 218: Hongmen Banquet and a Drop: The "Fengmu Tiada" Entry

Chapter 305: Chapter 218: Hongmen Banquet and a Drop: The "Fengmu Tiada" Entry

The Jin Pharmaceutical Group might have been paying close attention, but the two scientists were extremely busy and had very high standards. As far as they were concerned, a single paper in a special issue of *Cell*—which was merely a superficial overview of a conceptual new drug called "Fengmu Tiada"—wasn’t enough to warrant a meeting with Wu Ting.

After all, Wu Ting had no background in pharmacology. He was a clinician—a surgeon—a complete outsider to the world of pharmaceutical R&D. So, even with Deng Feifei pulling strings for him, the two scientists wouldn’t give him the time of day.

In their eyes, a pointless conversation with Wu Ting was a waste of time that could be better spent conducting more clinical trials.

With Jin Yihong’s full support and trust, their R&D teams had already invested a great deal of funding and time. Jia Jun’s team, in particular, was on the verge of bringing their new drug to market and couldn’t afford to waste a single moment.

Lately, the closer Jia Jun’s team got to completing the clinical trials for the Yangzheng Xiujie Pill and entering the final review and approval phase, the more anxious and pressured they felt.

After all, a small, domestic pharmaceutical company like theirs could hardly compete with colossal international pharmaceutical giants.

If one of the top pharmaceutical companies were to release a competing product right before or at the same time as their launch, the consequences for a domestic drugmaker would be devastating.

After all, given a choice between two similar products, hospitals, doctors, and patients alike wouldn’t think twice about choosing the one from a top international pharmaceutical company.

That was why Jia Jun had practically been living at the R&D center lately, immersed in the project for the better part of each day.

Wu Ting was naturally disappointed that the two scientists had refused his request for a meeting.

’After all, if I can just have a significant interaction with those two top scientists, I might have a chance to unlock related terms in the pharmaceutical field.’

’The R&D for my new drug, Fengmu Tiada, depends on it!’

But just when he thought it was a fruitless endeavor, President Xie Bin of Pfizer Pharmaceutical Company presented Wu Ting with a legitimate and unmissable opportunity for a meeting.

Deng Feifei came to find Wu Ting right away.

"Wu Ting, your chance to meet and speak with Lou Musaang and Jia Jun is here. You need to seize this opportunity and prepare the questions you want to ask in advance."

"A while back, didn’t Xie Bin, the President of Pfizer Pharmaceutical Company’s Jin Country District, give a lecture at Jinggang University? He was deeply interested in your project. But then you ended up cooperating with our Jin Pharmaceutical Group instead."

"So, this time, President Xie is specifically bringing a team of top scientists from the Pfizer Jin Country Research Center in Xianglin City to our Jin Pharmaceutical Group for an inspection and exchange."

"This delegation is led by their research center’s chief scientist, Professor Xu Linjun. Professor Xu’s standing in the industry is top-tier."

"Most importantly, Professor Xu and our R&D center’s chief scientist, Lou Musaang, were classmates in the pharmacology department at Xingke University. This exchange is a reunion at the summit after many years!"

"A big reason for this meeting is your project. That’s why President Xie specifically requested your presence at this exchange."

"Having top experts of their generation in the pharmaceutical field, like Professor Xu, Professor Lou, and Professor Jia, all gathered in one room is a truly once-in-a-lifetime opportunity. This meeting will be incredibly valuable for the future of your project."

Deng Feifei had developed a great deal of respect and admiration for Wu Ting over this period, so she hoped he could gain some new ideas and inspiration from this exchange.

At the very least, she hoped he could get to know Jia Jun and Lou Musaang, leave a good impression, and lay the groundwork for future collaboration.

Wu Ting was, of course, overjoyed by Deng Feifei’s invitation.

...

...

「At the appointed time.」

The representatives of the three parties gathered in a conference room at the Jin Pharmaceutical Group’s R&D center.

For the hosts, the Jin Pharmaceutical Group: R&D center scientists Lou Musaang and Jia Jun, as well as the head of the Jin Pharmaceutical Group, Jin Yihong.

For the Pfizer Jin Country Research Center: Xu Kunlin, along with their Jin Country District President, Xie Bin.

And finally, for Wu’s Pharmaceutical Company: the second-in-command and acting R&D manager, Deng Feifei, and her boss, Wu Ting.

In recent times, Deng Feifei had come to fully embrace her role as the second-in-command of Wu’s Pharmaceutical Company.

The exchange meeting officially began, following the script designed and arranged by Xie Bin.

Xie Bin opened by expressing his regret at having narrowly missed the chance to work with Wu Ting’s team, conveying his high regard and praise for Wu Ting.

He also lavished praise on Wu Ting’s project and proposed the idea of investing in it for an equity stake.

Of course, this investment came with a series of special conditions. In short, after hearing them, Wu Ting rejected the offer outright.

In response to Wu Ting’s refusal, Xie Bin expressed his profound regret and disappointment.

He claimed that as the President of the Pfizer Group’s Jin Country District, he could only follow company regulations. He didn’t want those special conditions either, but his hands were tied.

After that, Xie Bin exchanged a few more pleasantries with Wu Ting.

Only then did he get to the main topic.

He proceeded to demonstrate a thorough analysis and an in-depth understanding of the progress of the "Yangzheng Xiujie Pill" project.

Jin Yihong and Jia Jun grew visibly tense.

In the meeting, Xie Bin remained silent, but Xu Kunlin directly put forth a plan to acquire the "Yangzheng Xiujie Pill" project.

He even named a sky-high price.